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N-ACETYLPROCAINAMIDE IS A LESS 
POTENT INDUCER OF T CELL AUTOREACTIVITY 
THAN PROCAINAMIDE 
BRUCE RICHARDSON, ELIZABETH CORNACCHIA, JOSEPH GOLBUS, JONATHAN MAYBAUM, 
JOHN STRAHLER, and SAMIR HANASH 
We have reported that an inhibitor of DNA 
methylation, 5-azacytidine, makes cloned, antigen- 
specific CD4+ T cells autoreactive, and that procaina- 
mide and hydralazine mimic this effect. Those results 
suggested that procainamide and hydralazine may in- 
duce autoimmunity by inhibiting DNA methylation and 
causing T cell autoreactivity. We report now that N- 
acetylprocainamide, a procainamide derivative that 
does not induce lupus, is also a DNA methylation 
inhibitor, but it is 100 times less potent than procaina- 
mide in inducing T cell autoreactivity. 
DNA methylation inhibitors induce expression 
of genes normally suppressed by mechanisms associ- 
ated with cytosine methylation (1) and, in certain 
systems, can change cellular phenotype and alter 
differentiation (2,3). We have previously reported that 
5-azacytidine (5-azaC), a DNA methylation inhibitor, 
made 4 cloned antigen-reactive T cells respond to 
autologous class I1 major histocompatibility complex 
(MHC) determinants without specific antigen, presum- 
ably by inducing expression of suppressed genes (4). 
This response was termed autoreactivity. 
In those studies, we demonstrated that the 5- 
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azaC-treated T cells responded to autologous but not 
allogeneic macrophages, and that monoclonal antibod- 
ies to class I1 but not class I MHC determinants would 
inhibit activation (4). Those results suggested the pos- 
sibility that similar inhibition of T cell DNA methylation 
in vivo could lead to an autoimmune disease. 
To determine if inhibitors of DNA methylation 
could produce an autoimmune disease, we tested 
whether 2 drugs known to induce a lupus-like syn- 
drome inhibit DNA methylation and induce T cell 
autoreactivity. We found that hydralazine (Hyd) and 
procainamide (Pca) mimicked the effects of 5-azaC on 
T cells by inducing T cell autoreactivity in these 
cloned lines and decreasing deoxymethylcytidine 
(d"C) content in T cell DNA, thus supporting the 
hypothesis that DNA methylation inhibitors may in- 
duce autoimmune disease ( 5 ) .  
To further test this hypothesis, we compared 
Pca and Hyd with structural analogs, using the assays 
previously developed. N-acetylprocainamide (Napa) 
is a procainamide derivative that rarely induces lupus 
( 6 4 ,  and hydralazine is a phthalazine (Phth) deriva- 
tive containing a hydrazine side chain (l-hydrazinoph- 
thalazine) (9,lO). Previously, investigators speculated 
that the hydrazine side chain of hydralazine may be 
responsible for the lupus-like syndrome (9); therefore, 
we compared Pca with Napa and Hyd with Phth, for 
the ability to induce T cell autoreactivity and inhibit 
DNA methylation. 
MATERIALS AND METHODS 
T cell cultures. CD4 + , cloned, tetanus toxoid (TTh 
reactive, interleukin-2 (IL-2tdependent T cell lines were 
generated and maintained as previously described (4 , l l ) .  
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Briefly, T cells were activated with TT in vitro, expanded 
with IL-2, cloned once by limiting dilution at 0.2 cells/well, 
and maintained by weekly rechallenge with fresh irradiated 
(2,000R) autologous antigen-presenting cells (APC) plus TT, 
and twice weekly addition of IL-2. The human leukemic 
Jurkat T cell line was cultured in RPMI 1640 containing 10% 
fetal calf serum (Hyclone, Logan, UT) and supplemented 
with 100 units/ml penicillin and 100 pdml  streptomycin. T 
cells were treated with Pca, Hyd, hydroxyurea (Hu), 5-azaC 
(all from Sigma, St. Louis, MO), Napa, or Phth (both from 
Aldrich Chemicals, Milwaukee, WI) for at least 4 days 
before testing. 
Proliferation assays. IL-2dependent T cells were 
washed free of IL-2 and cultured 16 hours in RPMI supple- 
mented with 20% human type AB serum without IL-2. Then, 
2 x lo4 cells were cultured with 10' irradiated (2,000R) 
autologous peripheral blood mononuclear cells in 200 pl 
RPMI:20% AB serum using round-bottom 96-well plates 
(Nunc plates; Gibco, Grand Island, NY). TT (Wyeth, Ma- 
rietta, PA) was used at 1:25-1:100 dilutions, and maximum 
responses were usually observed at 150. Proliferation was 
measured on day 3 by tritiated thymidine (3H-TdR) uptake, 
as previously described (4,l I). 
High performance liquid chromatography (HPLC) 
quantitation of d"C. Jurkat cells were treated with lO-'M to 
10-4M Pca, Napa, Hyd, Phth, Hu, or lO-'M 5-azaC. DNA 
was isolated 4-7 days later, using the method of Bell et a1 
(12). In addition, the DNA was treated with 100 pg/ml 
RNase (Sigma) at 37°C for 1-3 hours before precipitating 
with ethanol. The DNA was quantitatively hydrolyzed with 
DNase I ,  phosphodiesterase, and alkaline phosphatase as 
described (1 3), and the resultant nucleosides were separated 
by reverse-phase chromatography using a C,, column (par- 
ticle size 5p; Regis, Morton Grove, IL) with a mobile phase 
of 1% methanol in 0.01M acetate buffer (pH 5.3), at a flow 
rate of 1 ml/minute. 
The column was washed between samples with 30% 
methanol in the same buffer, and absorbance was monitored 
at 280 nm using a Model 440 detector (Waters, Milford, MA). 
Data were collected using a Waters Data Module. Fluoro- 
deoxyuridine was added to each sample as an internal 
standard, and deoxycytidine (dC) and d"C content was 
determined using peak area, relative to standard curves for 
dC and d"C. The d"C peak was identified by retention time 
and ultraviolet spectral analysis. Deoxymethylcytidine con- 
tent was expressed as a percentage of total dC: 
dmC x 100 
d"C + dC 
Statistical analysis. Results were compared using 
Student's t-test. 
RESULTS 
Induction of T cell autoreactivity by Pca, Hyd, 
Napa, and Phth. A cloned, CD4-bearing, TT-reactive 
T cell line (TT36C) was used to test whether Pca, 
Napa, Hyd, or Phth induces autoreactivity similar to 
5-azaC. The reactivity of this cell line is shown in 
Table 1. Response of TT36C T cell line to antigen-presenting 
cells (APC) plus tetanus toxoid (TT) 
TT36C + 
Experiment TT36C TT36C + APC APC + TT* 
1 610 ? 169 2,097 t 1,052 19,818 ? 401 
2 76 t 18 2,009 f 1,043 30,756 f 4,556 
3 102 -r- 55 114 ? 25 6,616 ? 361 
* Cells were cultured as described in Materials and Methods. 
Proliferation was measured on day 3 by tritiated thymidine ('H-TdR) 
incorporation. Values are the mean f SEM cpm of quadruplicate 
determinations, and maximal reactivities are shown. 'H-TdR uptake 
by peripheral blood mononuclear cells cultured alone was 400 f 126 
cpm (mean ? SEM of 3 experiments; range 27-561 cpm). 
Table 1. TT36C required APC and TT for activation 
and did not respond to APC alone. The T cell re- 
sponses to APC alone were not significantly greater 
than the sum of 3H-TdR incorporation by T cells and 
APC cultured separately. Peak responses differed be- 
tween experiments, possibly due to differences in cell 
number or viability, but in all cases optimal prolifera- 
tion was usually found at TT dilutions of 150. 
To compare the relative potencies of Pca with 
Napa and of Hyd with Phth in this assay system, 
TT36C was treated with a broad range of concentra- 
tions of these 4 drugs. Each treated line was cultured 
alone or challenged with autologous APCs with and 
then without an optimal amount of TT. 
Figure 1 illustrates the results of these experi- 
ments. The maximum antigen-induced proliferative 
response frequently varied among the treated lines; 
therefore, to compare results between the treated cell 
lines, the data in Figure 1 are expressed as the ratio of 
the T cell response to APC alone divided by the 
maximum antigen-induced response, expressed as a 
percentage, and the data are plotted against the con- 
centration of drug used to treat the cells. Both Pca and 
Napa induced autoreactivity ; however, approximately 
100 times as much Napa was required to induce a 
comparable amount of autoreactivity as Pca, indicat- 
ing that it is 100 times less potent in this assay. 
In other experiments testing autoreactivity in- 
duced by Pca and Napa, only 100 pM Napa consis- 
tently induced significant autoreactivity , while Pca 
induced autoreactivity between 10-6M and 10T4M. In 
contrast, in the experiment shown in Figure 1, both 
Hyd and Phth induced autoreactivity over the range of 
concentrations tested, and Phth induced a greater 
amount of autoreactivity at all concentrations tested. 
In other experiments, no significant differences 
were observed in the amount of autoreactivity induced 
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Figure 1. Comparison of antigen reactivity and drug-induced auto- 
reactivity. T cells were treated with the indicated concentrations of 
A, procainamide (Pca) or N-acetylprocainamide (Napa) or B, hydra- 
lazine (Hyd) or phthalazine (Phth). Four days later, the cells were 
cultured as described in Materials and Methods. Proliferation was 
measured by tritiated thymidine (3H-TdR) uptake on day 3. Results 
are expressed as the ratio of the T cell response to peripheral blood 
mononuclear cells (PBMC) divided by the maximum response to 
PBMC plus tetanus toxoid for each drug concentration tested. 
Values are the mean 2 SEM of quadruplicate determinations. 
3H-TdR incorporation of the T cells cultured alone was 411 ? 138 
cpm, and the antigen-induced response was 7,656 f 1,040 cpm 
(mean +. SEM of 12 determinations). 
by 10K6M and 10V5M Hyd; however, the decreased 
autoreactivity observed at 10-4M Hyd and 10-4M 
Phth was reproducible. Moreover, 10-4M is close to 
the maximum concentration of Hyd and Phth at which 
the cloned cells survive, and in some experiments this 
concentration was toxic, suggesting that the decreased 
autoreactivity observed may be due to a toxic effect on 
the cells. No such toxic effects were observed for Pca 
and Napa in the concentration range tested. 
Inhibition of DNA methylation by Pca, Napa, 
Hyd, and Phth. To test whether Pca, Napa, Hyd, or 
Phth inhibit DNA methylation, the human leukemic 
Jurkat T cell line was treated with various concentra- 
tions of these drugs. Similar concentrations of Hu 
served as a negative control, and 1 p M  5-azaC was a 
positive control. 
The cells were harvested 4-7 days later, 
washed, and the DNA isolated. Previous studies had 
demonstrated that 5-azaC gave maximal inhibition of 
DNA methylation on day 4, while Pca and Hyd 
inhibited maximally after 7 days of continuous culture 
with the drugs ( 5 ) .  The purified DNA was digested 
with DNase I ,  phosphodiesterase, and alkaline phos- 
phatase, and the resultant nucleosides were separated 
and quantitated by HPLC analysis. Figure 2 shows the 
decrease in d"C content induced by Pca, Napa, Hyd, 
Phth, and 5-azaC at the lowest concentration giving 
significant ( P  < 0.05) inhibition, expressed as the 
percentage of d"C content, compared with untreated 
controls. For reference, d"C represents 3.98 5 0.2% 
of total dC in Jurkat DNA (mean k SEM of 12 
determinations). 
Pca, Napa, Hyd, Phth, and 5-azaC significantly 
decreased d"C content, compared with untreated con- 
trols, while Hu failed to inhibit DNA methylation at 
similar concentrations. At lo-", Napa also de- 
creased d"C content (mean 5 SEM of 3 determina- 
tions 74 t 7%; P < O . l ) ,  as did 10-6M Pca (mean ? 
SEM of 3 determinations 56 ? 15%; P < 0.1). The 
decreases in d"C content induced by Pca, Napa, Hyd, 
and Phth were not significantly different at comparable 
concentrations, nor were they significantly different 
from that induced by 1 p M  5-azaC. All 4 drugs, 
however, gave significant methylation inhibition com- 
pared with untreated controls, and it is noteworthy 
that Napa gave some inhibition at 10-6M, a concen- 
tration that failed to induce autoreactivity . 
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Figure 2. Inhibition of DNA methylation. Jurkat cells were treated 
with IOV'M to 10-4M hydroxyurea (Hu), Pca, Napa, Hyd, Phth, or 
10-"M 5-azacytidine (5-azaC). Seven days later the cells were 
recovered, and the DNA was isolated and digested as described in 
Materials and Methods. The 5-azaC-treated cells were harvested 
after 4 days of treatment. Nucleosides were separated by high 
performance liquid chromatography, and deoxymethylcytidine 
(d"C) and deoxycytidine were quantitated. The d"C content was 
calculated as described in Materials and Methods. Values are the 
mean ? SEM, relative to untreated Jurkat cells, of 2 separate 
experiments for Hyd and Phth, and 3 separate experiments for Pca, 
Napa, 5-azaC, and Hu. The results represent the lowest concentra- 
tion of the drugs inducing significant (P  < 0.05) inhibition. The d"C 
content of untreated Jurkat cells was 3.98 ? 0.20% (mean k SEM 
of 12 determinations). See Figure 1 for other definitions. 
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DISCUSSION 
The experiments presented compare 2 drugs, 
known to induce a lupus-like syndrome, with analogs, 
using assays that test induction of autoreactivity and 
inhibition of DNA methylation in vitro. The data dem- 
onstrate that Pca, Napa, Hyd, and Phth each decreased 
d”C in DNA, thus resembling the effects of 5-azaC, a 
recognized inhibitor of DNA methylation (1,14). More- 
over, all 4 drugs induced autoreactivity in cloned, 
antigen-specific T cell lines, again similarly to 5-azaC. 
As was found with 5-azaC, at least a portion of the 
treated cells retained specificity for TT (4). These 
effects occurred at concentrations that are achieved in 
vivo by Pca and Hyd. Therapeutic levels of hydralazine 
are 0.5-5.0 p M  (15), and Pca levels achieved in vivo are 
in excess of 10 p M  (6,16). These results suggest that the 
lupus caused by Pca and Hyd may result, in part, from 
induction of autoreactive T cells in vivo. 
To test this hypothesis, we compared relative 
potencies of Pca and Napa and of Hyd and Phth in the 
autoreactivity assay. Napa is a Pca derivative that is 
an effective antiarrhythmic agent like Pca, but it rarely 
induces the lupus-like syndrome (6-8). Hyd is a Phth 
derivative containing a hydrazine side chain (9,lO). 
Hydrazine has been implicated in drug-induced lupus 
(17), and additionally is known to covalently react with 
thymidine and deoxycytidine ( 3 ) ,  leading to the spec- 
ulation that the hydrazine side chain of Hyd may be 
responsible for the lupus-like syndrome (9). 
Phth was found to be a potent inducer of T cell 
autoreactivity and a DNA methylation inhibitor like 
Hyd, suggesting that if these properties are involved in 
drug-induced lupus, the hydrazine side chain is not 
required. More interestingly, both Pca and Napa were 
found to induce autoreactivity; however, Napa was 
100 times less potent in inducing autoreactivity than 
Pca, suggesting that Napa may fail to induce lupus 
because insufficient concentrations are achieved in 
vivo to cause T cell autoreactivity. For this reason, 
Pca may be more “lupogenic” than Napa. 
When Pca and Napa were compared for the 
ability to inhibit DNA methylation, however, both 
drugs induced significant hypomethylation at 1 p M ,  a 
concentration at which Napa did not induce autoreac- 
tivity. This suggests that inhibition of DNA methylation 
may not always lead to T cell autoreactivity. Other 
investigators have observed a dissociation between the 
biologic effects and degree of hypomethylation when 
various methylation inhibitors were compared, and this 
may well be the case with Pca and Napa ( 3 ) .  
Alternatively, Jurkat, the leukemic T cell line 
used to measure DNA methylation, and TT36C, the 
IL-2-dependent line used to measure autoreactivity, 
may differ in their sensitivity to Pca and Napa. Ideally, 
autoreactivity and DNA methylation should be mea- 
sured in the same cell line; however, the MHC allele 
recognized by Jurkat cells is unknown, and insufficient 
numbers of T cells are obtainable from conventional 
cloning techniques to perform methylation studies, 
which require 30-50 x 10‘ cells per determination. 
The mechanism by which these drugs inhibit 
DNA methylation is unknown. 5-azaC is incorporated 
into newly synthesized DNA, where it covalently 
binds the methyltransferase that methylates cytidine in 
the newly synthesized DNA strand when 5-methyl- 
deoxycytidyldeoxyguanosine is recognized on the par- 
ent strand (18). Pca and Hyd bind DNA (19-21), and 
may interfere with the action of the methyltransferase, 
resulting in hypomethylation of the newly synthesized 
strand. 
Our findings support the contention that hydra- 
lazine and procainamide induce a lupus-like syndrome 
by causing T cell autoreactivity. In the chronic graft- 
versus-host model of lupus, CD4 + T cells responding 
to self-MHC determinants in the host cause a lupus- 
like disease (22), and the autoreactive cells induced by 
inhibitors of DNA methylation may mediate a similar 
process. Since DNA methylation inhibitors alter cel- 
lular phenotype and function by inducing gene expres- 
sion, it is reasonable to propose that T cell autoreac- 
tivity induced by these agents is mediated by a similar 
mechanism. 
It remains to be determined whether other 
agents that induce gene expression, such as viruses or 
ultraviolet light (23), could also induce autoimmunity 
by activating certain genes determining T cell auto- 
reactivity. Identification of the specific genes activated 
by DNA methylation inhibitors will be crucial in 
testing their role in T cell autoreactivity. 
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